ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus. AASLD, American Association for the Study of Liver Disease; EASL, European Association for the Study of the ...
Chronic hepatitis B (CHB) remains a significant global health ... 24 and 48 weeks for TMF were 56.82% and 70.45% (according to AASLD 2018 standards). In the TE group, VR rates at 24 and 48 weeks ...
Hosted on MSN2mon
Promising New Data from Hepatitis B Trial by Arbutus and BarinthusThe trial, which focuses on chronic hepatitis B (cHBV), shows potential advancements in treatment options for the disease. The latest findings involve Group C participants who received a ...
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company, today announced recent progress in the ongoing clinical development of its ...
Chronic hepatitis B (CHB) remains a significant global health ... 24 and 48 weeks for TMF were 56.82% and 70.45% (according to AASLD 2018 standards). In the TE group, VR rates at 24 and 48 weeks ...
International Approvals, November 22, 2013 AASLD Hepatitis C Viral Suppression Reduces Liver Morbidity, Death Only 1 in 4 patients with hepatitis C had been treated and even fewer achieved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback